...We Welcome You To The Resverlogix HUB In The AGORACOM COMMUNITY!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** Trial is Fully Enrolled and Top-Line Results Expected Q1 2019

Free
Message: A longtime holder

It wasn't my primary point of concern, but I did touch on the FDA "modifications" with Don.  The FDA is a typical bureaucracy from the way he described it.  It seems that just when the compnay thinks they've satisfied all the requirements, another branch will inject itself in the process with a new list of demands to be met....almost like playing whack a mole.

I think they could have worded that news back on July 25th, but it does say they received an approval "pathway", so it seems the FDA might have added a few obstacles along that path, hurdles that still have to be cleared.

On a different note I'm noticing the bid/ask at $1.75 both ways.....obviously that will change, I don't have much faith in pre-market quotes, but hopefully we see a gap up.  

Share
New Message
Please login to post a reply